A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer
- First Online:
- 752 Downloads
In order to confirm the impact of adding S-1 to gemcitabine, we conducted a randomized phase II study to compare the combination therapy of gemcitabine plus S-1 to gemcitabine monotherapy in patients with advanced biliary tract cancer.
Sixty-two patients with advanced cholangiocarcinoma or gallbladder cancer were randomized to either the combination therapy of gemcitabine and S-1 (gemcitabine 1,000 mg/m2 on days 1 and 15 and S-1 40 mg/m2 b.i.d. on days 1–14, repeated every 4 weeks) or gemcitabine monotherapy (gemcitabine 1,000 mg/m2 on days 1, 8, and 15, repeated every 4 weeks). The primary endpoint of this study was response rate, and the regimen which showed the better response rate was selected as a candidate of phase III study. Tumor response was assessed every two cycles using Response Evaluation Criteria in Solid Tumors criteria version 1.0.
The response rates of the combination therapy and the monotherapy were 20.0 and 9.4 %, respectively. The median time-to-progressions and overall survivals of these two treatments were nearly the same (5.6 vs. 4.3 months; 8.9 vs. 9.2 months). Adverse events occurred more frequently in the combination arm.
The combination therapy of gemcitabine and S-1 showed the better response rate, but the superiority of this combination therapy was not clear in total. Because the standard of care changed to the combination therapy with gemcitabine and cisplatin during this study, it is difficult to select this combination therapy with a 4-week regimen as a candidate of phase III study.
KeywordsBiliary tract cancer Gemcitabine S-1 Chemotherapy Randomized control study
- 1.Vital Statistics Japan (Ministry of Health, Labour and Welfare). http://ganjoho.jp/professional/statistics/statistics.html
- 6.Park I, Lee JL, Ryu MH, Kim TW, Chang HM, Lee SS, Sohn BS, Kim EK, Park do H, Lee SS, Suh DW, Lee SK, Kim MH, Lee J (2009) Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients. Oncology 76:126–132PubMedCrossRefGoogle Scholar
- 7.Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K (2012) Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 30:708–713PubMedCrossRefGoogle Scholar
- 8.Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M (2010) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65:1101–1107PubMedCrossRefGoogle Scholar
- 9.Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E (2011) A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 67:1429–1434PubMedCrossRefGoogle Scholar
- 12.Ueno M, Okusaka T, Mizusawa J, Takashima A, Morizane C, Ikeda M, Hamamoto Y, Ishii H, Hara H, Fukutomi A, Furukawa M, Nagase M, Yamaguchi T, Yamao K, Nakamori T, Ioka T, Iguchi H, Miyazaki H, Boku N, Furuse J (2012) Randomized phase II trial of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: results of the Japan Clinical Oncology Group study (JCOG0805). J Clin Oncol 30(Suppl; abstr 4031)Google Scholar
- 13.Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Kimura F, Miyazaki M (2013) Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol 20:318–324Google Scholar